Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 10/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.45 |
| ▸ | CCR5 | P51681 | 4/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2877885 | 1.00 | MCHR1 (0.45) | MCHR1KCNH2CCR5ACHEGSK3B | |
| SCHEMBL2885380 | 1.00 | MCHR1 (0.45) | MCHR1KCNH2CCR5ACHEGSK3B | |
| SCHEMBL2882985 | 0.92 | MCHR1 (0.48) | MCHR1KCNH2CCR5ACHEGSK3B | |
| SCHEMBL2885379 | 0.92 | MCHR1 (0.48) | MCHR1KCNH2CCR5ACHEGSK3B | |
| SCHEMBL2882986 | 0.92 | MCHR1 (0.48) | MCHR1KCNH2CCR5ACHEGSK3B | |
| SCHEMBL2883011 | 0.91 | MCHR1 (0.48) | MCHR1KCNH2CCR5ACHEGSK3B | |
| SCHEMBL2883015 | 0.91 | MCHR1 (0.48) | MCHR1KCNH2CCR5ACHEGSK3B | |
| SCHEMBL2883058 | 0.91 | MCHR1 (0.46) | MCHR1KCNH2CCR5ACHEGSK3B | |
| SCHEMBL2883055 | 0.91 | MCHR1 (0.46) | MCHR1KCNH2CCR5ACHEGSK3B | |
| SCHEMBL2880249 | 0.89 | MCHR1 (0.46) | MCHR1KCNH2CCR5ACHEGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324049-A1 | DIARYL KETIMINE DERIVATIVE HAVING ANTAGONISM AGAINST MELANIN-CONCENTRATING HORMONE RECEPTOR | MSD K.K. (JP) | 2010-12-23 | — | — | US | claimed |
| US-20100324049-A1 | DIARYL KETIMINE DERIVATIVE HAVING ANTAGONISM AGAINST MELANIN-CONCENTRATING HORMONE RECEPTOR | MSD K.K. (JP) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324049-A1 | DIARYL KETIMINE DERIVATIVE HAVING ANTAGONISM AGAINST MELANIN-CONCENTRATING HORMONE RECEPTOR | MC1R, MCHR1, MCHR2 | MCHR1 2/4885KCNH2 565/4885CCR5 3055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.